A Pragmatic, Multi-centre, Open-label, Randomized, 12-month, Parallel Group, Superiority Study to Compare the Effectiveness of Subcutaneous Buprenorphine Depot (Sublocade®) vs Daily Sublingual Buprenorphine With Naloxone (Suboxone®) for the Treatment of Opioid Use Disorder
Latest Information Update: 28 Oct 2022
At a glance
- Drugs Buprenorphine (Primary)
- Indications Opioid-related disorders
- Focus Therapeutic Use
- Acronyms STOPIT
Most Recent Events
- 28 Oct 2022 New trial record